Operational update & investor webinar
GenIP Plc
("GenIP" or the "Company")
Operational update & investor webinar
GenIP to bring full operation and management of Invention Evaluator in-house,
strengthening technology capabilities and profit margins
GenIP plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, announces it has given notice on its agreement with Phosphorix Ltd ('Phosphorix') as part of a planned transition to bring full operation and management of the Invention Evaluator platform in-house.
This is a strategically important and positive development for GenIP which will enhance governance, strengthen operational resilience, and accelerate the Company's ability to innovate and scale its technology platform. Following an agreed three-month transition period, during which Phosphorix will continue to provide support services, GenIP will possesses the full internal resource, technical expertise, and leadership required to manage and scale the Invention Evaluator platform independently.
Bringing production of Invention Evaluator in-house delivers clear and immediate operation and financial benefits, including;
● Improved margins - the Company will retain the full product margin previously shared under the Phosphorix agreement.
● Cash savings - the monthly fixed fee and per-report charges will no longer apply.
● Product Agility - direct ownership of the development roadmap enables faster iteration and enhanced scalability.
● Clearer governance - the removal of related-party dependencies strengthens compliance with the QCA Code and enhances investor confidence.
Appointment of Chief Product Officer
As part of the transition, the Company has appointed Harin Vaghela as Chief Product Officer ('CPO') who will be responsible for managing the entire Invention Evaluator platform in-house as well as driving the Company's product strategy and technology roadmap. Harin brings over 15 years' experience delivering AI-powered enterprise platforms at organizations including Pasabi, LVMH, and Black Swan Data.
Investor Webinar via CMC CapX Spotlight
Melissa Cruz, CEO and Kevin Fitzpatrick, CFO, will host an investor webinar and Q&A session via CMC CapX Spotlight on 24 September 2026 at 17:00 BST.
The webinar is open to all existing and potential shareholders. Questions can be submitted in advance via GenIP@walbrookpr.com or at any time during the live presentation.
Investors can register for free and join the webinar by clicking HERE.
Investors who are not yet registered with CMC CapX Spotlight will be prompted to create a free account to access the session.
A recording of the webinar will be available on the Company website soon after the event.
Melissa Cruz, CEO of GenIP, commented:
"Bringing Invention Evaluator entirely in-house is a logical and commercially beneficial step for GenIP. By internalising our technology stack and reducing third-party dependencies, we expect to improve product margins while gaining greater control over our development roadmap. With the infrastructure and product leadership now in place, we are well positioned to scale our AI-enabled solutions more efficiently and support the next phase of GenIP's growth."
For further information regarding GenIP, please visit www.genip.ai, or contact:
GenIP Plc
Melissa Cruz, CEO
Via Walbrook PR
Beaumont Cornish Limited (Nominated Adviser)
Roland Cornish / Asia Szusciak / Andrew Price
Tel: +44 (0) 20 7628 3396
AlbR Capital Limited (Joint Broker)
Colin Rowbury
Jon Belliss
Tel: +44 (0) 20 7399 9427
CMC Markets (Joint Broker)
Douglas Crippen
Tel: + 44 (0) 203 003 8632
Walbrook PR (Financial PR)
Alice Woodings
William Turner
Tel: +44 (0) 7407 804 654
Tel: +44 (0) 7407 020 470
focusIR (Investor Relations)
Kat Perez
Dr Paul Cornelius
Tel: +44 (0) 20 4570 2234
Tel: +44 (0) 20 4570 2246
About GenIP
GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.
Service Offerings
GenIP operates through two synergistic service lines:
Service
Description
Value Proposition
Invention Intelligence Product Suite
AI-powered market intelligence reports assessing the commercial potential of emerging technologies
Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy
IP Commercialisation Services
End-to-end engagement to help research organisations commercialise innovations
Provides cost-effective, broad support to achieve our clients' strategic objectives
Together, these services form a unified GenAI-enabled platform for innovation triage and execution.
Vision & Strategy
GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:
· Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
· Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.· Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDUPDBCGDCISGDGLI
